This Funding Opportunity Announcement (FOA) solicits applications that will advance understanding of vaccine regimens and immune responses that sustainably suppress virus in HIV-infected individuals. The FOA will support small, multi-arm, comparative clinical trials designed to identify correlations between levels of induced immune response and HIV virologic control. Vaccines may be combined with adjuvants and/or other modifiers of the immune response to HIV.
he FETP graduates, staff and trainees are important assets and help build sustainable public health capacity in their countries. Through public health conferences they share field epidemiology experiences and present work investigations through oral and poster presentations. This collaboration reinforces best practices in applied epidemiology, training, surveillance, and response and introduces new tools, concepts, and training materials. However, the region’s FETPs can be more effective if their collaboration extends beyond scientific conferences. Network development can enhance surveillance, investigation and response capacity globally through regular communication and exchange of information and allow for more robust response to regional and national public health threats. In 2009, the FETPs in the East Mediterranean Region (EMRO) began to organize a network in the Middle East that partner with MOH FETP representatives, CDC and EMRO closely collaborate to strengthen existing national FETPs and regional disease surveillance. This close collaboration and networking among programs is critical as the globe faces new and re-emerging public health threats. The recent outbreaks of Ebola and Zika viruses clearly demonstrate the need for strong local and regional programs that can mobilize rapid response teams quickly and assist countries and global partners to control disease and strengthen public health infrastructure.
This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasizes studies in a variety of settings including ambulatory care, hospitals (and specific sites within hospitals including specialty wards, intensive care units and emergency departments), assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programs. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection and/or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.
The Communications, Circuits, and Sensing-Systems (CCSS) Program supports innovative research in circuit and system hardware and signal processing techniques. CCSS also supports system and network architectures for communications and sensing to enable the next-generation cyber-physical systems (CPS) that leverage computation, communication, and sensing integrated with physical domains. CCSS invests in micro- and nano-electromechanical systems (MEMS/NEMS), physical, chemical, and biological sensing systems, neurotechnologies, and communication & sensing circuits and systems. The goal is to create new complex and hybrid systems ranging from nano- to macro-scale with innovative engineering principles and solutions for a variety of applications including but not limited to healthcare, medicine, environmental and biological monitoring, communications, disaster mitigation, homeland security, intelligent transportation, manufacturing, energy, and smart buildings. CCSS encourages research proposals based on emerging technologies and applications for communications and sensing such as high-speed communications of terabits per second and beyond, sensing and imaging covering microwave to terahertz frequencies, personalized health monitoring and assistance, secured wireless connectivity and sensing for the Internet of Things, and dynamic-data-enabled autonomous systems through real-time sensing and learning.
The Electronics, Photonics and Magnetic Devices (EPMD) Program supports innovative research on novel devices based on the principles of electronics, optics and photonics, optoelectronics, magnetics, opto- and electromechanics, electromagnetics, and related physical phenomena. EPMD's goal is to advance the frontiers of micro-, nano- and quantum-based devices operating within the electromagnetic spectrum and contributing to a broad range of application domains including information and communications, imaging and sensing, healthcare, Internet of Things, energy, infrastructure, and manufacturing. The program encourages research based on emerging technologies for miniaturization, integration, and energy efficiency as well as novel material-based devices with new functionalities, improved efficiency, flexibility, tunability, wearability, and enhanced reliability.
The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
The purpose of this Funding Opportunity Announcement (FOA) is to invite R03 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
LUNGevity's Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas.
Applicants must be within the first five years of their faculty appointment.
The Career Development Awards are mentored awards; a mentoring plan is part of the required submission.
Projects that will be funded in 2018 are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy.
Career Development Awards may be for a maximum of $300,000:
$100,000 per year for 3 years
The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
The purpose of this Funding Opportunity Announcement is to invite applications for innovative clinical, and preclinical/translational research to develop therapeutic vaccine strategies to improve treatment outcomes of active tuberculosis (TB) in the presence or absence of HIV co-infection.
The purpose of this Funding Opportunity Announcement (FOA) is to invite research project applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
The intent of the FY17 ERP IDA is to solicit research to understand the magnitude and underlying mechanisms of PTE. The FY17 ERP IDA offers two levels of funding. Funding Level I is intended to support high-risk or high-gain research from Principal Investigators (PIs) at or above the level of a postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent). Note that PIs submitting Funding Level I applications will be required to verify their eligibility for this award. Funding Level II is intended to support a more mature, hypothesis-driven research project. To be considered for an FY17 ERP IDA Funding Level II, the PI must be an independent investigator at or above the level of Assistant Professor (or equivalent). While not required, applications to either Funding Level I or II should provide relevant preliminary data. Preliminary data for either Funding Level may come from the PI's published work, pilot data, or from peer-reviewed literature. The requested budget level should be appropriate for the scope of research proposed.For Funding Level I:The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $300,000. The maximum period of performance is 2 years. For Funding Level II:The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $500,000. The maximum period of performance is 3 years. FY17 ERP IDA Focus Areas: The research impact for the FY17 ERP IDA is expected to benefit the military, Veteran, and civilian communities.
Undertake research activities that would entail implementing and evaluating community-based efforts to fight the opioid overdose epidemic; and Support and promote the partnership of law enforcement and public health agencies, whose collaboration is critical to reducing overdose and other harms of opioid (mis)use. This ongoing opioid overdose epidemic presents new challenges to public health and public safety officials, medical professionals, local communities, and other stakeholders invested in curbing rates of accidental death. Preparing regional and community leaders to respond effectively to the public health emergency that is today's opioid overdose crisis (and be prepared to take on that crisis as it evolves tomorrow) is essential for achieving the shared goal of preventing fatal overdose and saving lives. ONDCP expects to award one Federal grant under the Combating Opioid Overdose through Community-Level Intervention Initiative for a 1-year period, beginning approximately September 2017. The successful non-Federal entity (NFE) will conduct research activities that entail implementing and evaluating community-based efforts to fight the opioid overdose epidemic. These activities will be focused on the regions of the United States with some of the highest rates of fatal and non-fatal opioid-related overdoses and will work to coordinate the often decentralized state and local efforts to assess and respond to opioid-related overdoses.
Timely and reliable laboratory data are an essential component of a well-functioning national health system. This FOA will support strengthening the quality, accessibility, and sustainability of the NHLS across a six-tiered network, i.e., at the national, zonal, regional, district, health center, and dispensary levels. Technical assistance will focus on improving the quality assurance of HIV rapid testing, TB microscopy and GeneXpert; Early Infant Diagnosis (EID) and Viral Load (VL) testing; establishment and maintenance of efficient sample referral system and transport networks; implementation of laboratory Quality Management Systems; implementation of Laboratory Information Management Systems; scale up of EID and VL monitoring programs; quantification and forecasting of laboratory commodities; HIV Drug Resistance Surveillance; and, effective use of laboratory data for program management.
The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate tools and resources to facilitate the detailed analysis of brain microconnectivity. Novel and augmented techniques are sought that will ultimately be broadly accessible to the neuroscience community for the interrogation of microconnectivity in healthy and diseased brains of model organisms and humans. Development of technologies that will significantly drive down the cost of connectomics would enable routine mapping of the microconnectivity on the same individuals that have been analyzed physiologically, or to compare normal and pathological tissues in substantial numbers of multiple individuals to assess variability. Advancements in both electron microscopy (EM) and super resolution light microscopic approaches are sought. Applications that propose to develop approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged. Proof-of-principle demonstrations and/or reference datasets enabling future development are welcome, as are improved approaches for automated segmentation and analysis strategies of neuronal structures in EM images.
This NOFO will support implementation and acceleration of comprehensive HIV prevention, care, and treatment programs for HIV/AIDS epidemic control in Fort Portal Region of Uganda. This will entail implementation of comprehensive HIV/AIDS services in line with the new WHO guidelines,including targeted HIV testing services (HTS) to find more people living with HIV (PLHIV), especially men and key and priority populations (KP/PP) through HIV care and treatment; TB/HIV prevention, diagnosis, and treatment;elimination of Mother-to-Child Transmission (eMTCT); Voluntary Medical Male Circumcision (VMMC); services for orphans and vulnerable children (OVC); and associated laboratory and strategic information (SI) services through a health systems strengthening approach. Additionally, the recipient will work closely with the Ministry of Health (MOH) to strengthen the technical capacity of regional structures and District Health Teams (DHTs) for an effective public health decentralized HIV/AIDS response. Expected outcomes include improved access,coverage, and quality of HIV services ensuring 90% of PLHIV know their status;90% of people diagnosed with HIV infection receive antiretroviral therapy (ART); and 90% of those on treatment are virally suppressed.
JDRF provides seed funding for highly innovative research with significant potential to accelerate the mission of JDRF. Proposals should address key outstanding questions and have the potential to lead to a change in the current paradigm or conventional wisdom and/or lead to a groundbreaking discovery. Preliminary data is not required in the proposal but the underlying premise, goal, or hypothesis must be plausible and testable and the proposal must be focused with a well-defined goal that is achievable within the timeframe of the award.
Subject to funding availability, STAR is a five-year cooperative agreement. The Office of Professional Development and Management Support within the Bureau for Global Health will manage the Award. The Award covers all core-funded activities under this Agreement, and may receive both USAID core and field support funds, from a variety of accounts and earmarks. Applicants are encouraged to propose creative collaborative partnerships with other USG agencies and/or international organizations, NGOs, private voluntary organizations, and firms to implement activities under this program. Proposing at least one new partner in response to this NFO is also highly desirable. "New partners" are defined as organizations that have never received Bureau for Global Health funding as either a direct or sub-recipient. Under this definition, organizations that have been directly funded by a USAID Mission bilateral program or have received USAID Regional Bureau funding will be considered a new partner. Partnerships should be of manageable size with relationships and responsibilities clearly defined.
The goal of the K12 Institutional Career Development Program in HIV-related Heart, Lung, Blood, and Sleep (HLBS) research is to encourage institutions to develop and sustain programs that support inter-disciplinary, intensive mentored research training and career development for junior PhDs and MDs in AIDS co-morbidities as well as cell and gene therapies for HIV cure and prevention of HIV transfusion transmission.
Solicits applied research in support of HRP goals and objectives. This response area is Appendix A of the Human Exploration Research Opportunities (HERO) NRA (80JSC017N0001). Proposals are solicited by NASA in the area of Space Radiobiology Tissue Sharing: Research Proposing the Use of Archived Tissue Samples or Samples from Ongoing Experiments. Appendix A Step-1 proposals are due September 12, 2017. Invited Appendix A Step-2 proposals are due December 5, 2017. All categories of United States (U.S.) institutions are eligible to submit proposals in response to the NRA. Principal Investigators may collaborate with universities, Federal Government laboratories, the private sector, and state and local government laboratories. In all such arrangements, the applying entity is expected to be responsible for administering the project according to the management approach presented in the proposal. NASA's policy is to conduct research with non-U.S. organizations on a cooperative, no exchange-of-funds basis.
